"We have the most data on the UK variant. That doesn't suggest that
it will be any less well protected against by the vaccine," said Wei
Shen Lim, chair of Covid-19 Immunisation on Britain's Joint
Committee on Vaccination and Immunisation.
Asked specifically about the South African variant, he said that
Oxford-AstraZeneca vaccine trials had been conducted in South Africa
which was an advantage in terms of data collection.
"We're told that very very soon, the Oxford and AZ trials may be
able to examine in quite some detail whether their vaccine will
protect against the new variant. I think that is a matter of weeks."
(Reporting by Alistair Smout and Estelle Shirbon; editing by William
James)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |